Previous Article | Next Article 
Molecular and Cellular Biology, November 2001, p. 7416-7428, Vol. 21, No. 21
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.21.7416-7428.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Common Regulation of Growth Arrest and
Differentiation of Osteoblasts by Helix-Loop-Helix Factors
Noriko
Funato,1,2
Kiyoshi
Ohtani,1
Kimie
Ohyama,2
Takayuki
Kuroda,2 and
Masataka
Nakamura1,*
Human Gene Sciences
Center1 and Maxillofacial
Orthognathics,2 Tokyo Medical and Dental
University, Bunkyo-ku, Tokyo 113-8510, Japan
Received 18 April 2001/Returned for modification 23 May
2001/Accepted 6 August 2001
 |
ABSTRACT |
Cellular differentiation entails the coordination of cell cycle
arrest and tissue-specific gene expression. We investigated the
involvement of basic helix-loop-helix (bHLH) factors in differentiation of osteoblasts using the human osteoblastic cell line MG63. Serum starvation induced growth arrest at G1 phase, accompanied
by expression of cyclin-dependent kinase inhibitor
p21WAF1/Cip1. Reporter assays with the p21 gene promoter
demonstrated that the combination of E2A (E12 or E47) and
coactivator CBP was responsible for p21 induction independent of p53.
Twist inhibited E2A-CBP-dependent activation of the exogenous and
endogenous p21 promoters. Ids similarly inhibited the exogenously
transfected p21 promoter; however less antagonistic effect on the
endogenous p21 promoter was observed. Twist was predominantly present
in nuclei in MG63 cells growing in complete medium, while it localized
mainly in the cytoplasm after serum starvation. The fibroblast growth
factor receptor 3 gene (FGFR3), which generates signals
leading to differentiation of osteoblasts, was found to be controlled
by the same transcriptional regulation as the p21 gene. E2A
and Twist influenced alkaline phosphatase expression, a consensus
marker of osteoblast differentiation. Expression of E2A and FGFR3 was
seen at the location of osteoblast differentiation in the calvaria of
mouse embryos, implicating bHLH molecules in physiological osteoblast
differentiation. These results demonstrate that a common regulatory
system is involved in at least two distinct steps in osteoblastic
differentiation. Our results also provide the molecular basis of
Saethre-Chotzen syndrome, caused by mutations of the TWIST
and FGFR3 genes.
 |
INTRODUCTION |
The development and
remodeling of bone require the differentiation of osteoblasts from
undifferentiated proliferating mesenchymal osteoprogenitor cells.
Unregulated differentiation of osteoblasts causes craniofacial and limb
anomalies, such as Saethre-Chotzen syndrome (acrocephalosyndactyly type
III; OMIM 101400), one of the most common genetic conditions with
craniosynostosis. The molecular basis of mechanisms that induce the
differentiated osteoblastic phenotype is poorly understood.
Cell differentiation is a consequence of a coordinated sequence of
biochemical events associated with morphological changes, including
arrest in G1 phase followed by irreversible exit
from the cell cycle and a timely ordered expression of tissue-specific genes. Cell proliferation and terminal differentiation are usually mutually exclusive. Among multiple mechanisms involved in the control
of terminal differentiation, cell cycle arrest through inactivation of
cyclin-dependent kinases (CDKs) is likely to be a central feature
(46). p21WAF1/Cip1 is an inhibitor of CDKs
(26) and is transcriptionally regulated in p53-dependent
(17) and -independent manners (46).
The E2A proteins belong to the basic helix-loop-helix (bHLH) family of
transcriptional regulatory proteins, functioning as dimers via a
helix-loop-helix (HLH) domain (40). The E2A
gene encodes two alternatively spliced products, E12 and E47, which differ in their bHLH domains and hence their DNA-binding properties (40, 64). E47 has been demonstrated to activate
p21 gene expression in HeLa cells (52). In
addition, E2A proteins have been shown to be involved in regulation of
growth arrest (50) and to recruit coactivator p300/CBP
(cyclic AMP-responsive element binding factor CREB-binding protein)
(11, 16). The dominant-negative-type HLH Id proteins,
which contain functional HLH dimerization motifs but which lack the
DNA-binding basic region, have been shown to interact with other bHLH
proteins and block their DNA-binding activity (4).
The bHLH protein Twist is expressed in mesodermal and cranial neural
crest cells during embryogenesis in both invertebrate and vertebrate
development (3, 19, 65, 69). Expression of Twist has been
implicated in the inhibition of differentiation of multiple cell
lineages including muscle (27, 62), cartilage (27), and bone cells (35, 39, 55). Twist
directly interacts with E12 and inhibits the expression of the muscle
creatine kinase gene (MCK) (24, 62), suggesting
its involvement in myogenesis.
The fibroblast growth factor receptor 3 (FGFR3) signaling pathway
results in upregulation of genes that are related to osteoblast differentiation, including the genes for osteopontin, osteonectin, and
osteocalcin (10). FGFR3 is detected in sutural osteogenic fronts, and Twist expression and FGFR3 expression are mutually exclusive (55). After birth cranial sutures are the
primary site of osteoblast differentiation and bone formation in the
calvaria. Saethre-Chotzen syndrome is characteristic of skull deformity due to craniosynostosis, the premature fusion of the cranial sutures. This syndrome is caused by mutations in the gene encoding Twist or
FGFR3 (18, 28, 56). The question, then, is whether Twist and FGFR3 are in the same or parallel developmental pathways in calvarial bone development.
To this end, we examined how these bHLH proteins are involved in
transcriptional regulation of cell cycle arrest (p21) and differentiation (FGFR3) in a human osteoblastic cell line MG63. Our
results clearly show that E12 and E47 induce transcription of the
p21 gene, resulting in cell cycle arrest in a
p53-independent manner. This induction is inhibited by Twist and Ids.
The same is true for the regulation of FGFR3 expression, demonstrating that common transcriptional regulation controls cell cycle arrest and
differentiation of osteoblasts. Our results also provide a molecular
basis for the pathogenesis of Saethre-Chotzen syndrome.
 |
MATERIALS AND METHODS |
Cell culture.
The human osteosarcoma osteoblast-like cell
line MG63, which is negative for p53 (9), was cultured in
Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine
serum (FBS) at 37°C under a humidified atmosphere of 5%
CO2. For induction of cell cycle arrest and
differentiation, cells were cultured in DMEM containing 0.1 or 2% FBS
with or without 1,25-dihydroxyvitamin D3
[1,25-(OH)2D3; 10
8 M] (Biomol
Research Laboratories).
Cell cycle analysis.
MG63 cells (105 cells/dish
60 mm in diameter) were cultured in DMEM containing either 0.1, 2, or
10% FBS and treated with or without
1,25-(OH)2D3 (10
8 M).
Cells were harvested by trypsinization, fixed with a
fluorescence-activated cell sorter (FACS) lysis solution (Becton
Dickinson), and permeabilized with a FACS permeabilization solution
(Becton Dickinson). After being washed with phosphate-buffered saline
(PBS), the cells were resuspended in staining solution containing
propidium iodide (50 µg/ml) and RNase A (50 µg/ml) and analyzed for
their DNA content with a FACScan (Becton Dickinson).
Plasmid construction.
An expression plasmid for Twist was
constructed by cloning the XhoI-XbaI fragment of
human Twist cDNA into pcDNA3 (Invitrogen). A point mutation (Y103X) was
introduced into the Twist coding region by site-directed mutagenesis,
generating pCMV-Twist (Y103X). The mutation was confirmed by DNA
sequencing. Full-length cDNAs encompassing the respective coding
regions of human E12 and E47 in pSP64 vector and human vitamin
D3 receptor (hVDR) in p91023B were cloned into pcDNA3,
generating pCMV-E12, pCMV-E47, and pCMV-hVDR, respectively. Mammalian
expression vectors for Id1, Id2, and the E12 N-terminal deletion mutant
1-507 (amino acids [aa] 508 to 654) were described elsewhere
(25). p21 cDNA was ligated in the sense or antisense
orientation, generating pCMV-p21 and pCMV-p21as. The expression plasmid
for CBP (pRSV-CBP) was a generous gift from T. Nakajima of the
University of Tsukuba (42). The p21-luc reporter construct
(a gift from X.-F. Wang, Duke University) carries the 2.4-kb
HindIII fragment of the p21 promoter in the pGL3-basic vector (Promega) (13). p21 promoter mutants p21-1.8kb-luc,
p21-220bp-luc, and p21-del PvuII-luc were produced by
deletion of the XhoI and TthIII1, XhoI
and PstI, and PvuII and PvuII
fragments from the p21-luc construct. The 1.5-kb
NcoI-SphI fragment of the FGFR3 promoter from
cosmid clone pc385.12 containing the human FGFR3 genomic fragment
(47) was inserted into the pGL2-basic vector (Promega),
thus generating FGFR3-luc. FGFR3 promoter mutants FGFR3-1.0kb-luc, FGFR3-0.7kb-luc, and FGFR3-0.5kb-luc were produced by deletion of the
NcoI and HincII, NcoI and
XhoI, and NcoI and PvuII fragments from the FGFR3-luc construct. The simian virus 40 nuclear localization signal sequence was fused to pEGFP-C2 (Clontech), generating vector pnGFP, expressing green fluorescent protein localized in the nucleus.
Transient transfection and luciferase assay.
Subconfluent
cultures of MG63 cells (2 × 105 cells/dish 60 mm in
diameter) were transfected with a total of 10 µg of expression and
reporter plasmids by the calcium phosphate method together with
-galactosidase (
-Gal) expression vector pCMV-
-gal, which was
used as an internal control to monitor the transfection efficiency. Total amounts of transfected DNA were equalized by the addition of
empty vectors pcDNA3 and pRc/RSV. After incubation overnight with the
DNA precipitate, cells were then cultured in DMEM containing 0.1, 2, or
10% FBS for a further 48 h for luciferase assay and for a further
72 h for immunostaining. Luciferase activities were assayed using
the luciferase assay system (Promega) and normalized to
-Gal
activities, which were determined by the method of Rose and Botstein
(57). All assays were performed at least three times in
duplicate, and representative data are presented. The results are the
means of different experiments ± standard errors.
Immunofluorescence staining.
Cells were fixed in PBS with
3.7% formaldehyde, permeabilized with Triton X-100 (0.1%) in PBS, and
then treated with serum to block nonspecific binding sites. Polyclonal
rabbit antibodies against E2A (sc-349; Santa Cruz Biotechnology), Id1
(sc-488; Santa Cruz Biotechnology), HEB (sc-357; Santa Cruz
Biotechnology),
-Gal (Zymed), and FGFR3 (sc-123; Santa Cruz
Biotechnology), polyclonal goat antibodies raised against a peptide
corresponding to an amino acid sequence at either the amino terminus
(sc-6070; Santa Cruz Biotechnology) or the carboxyl terminus (sc-6269;
Santa Cruz Biotechnology) of human Twist, and a mouse monoclonal
antibody to human p21 (sc-817; Santa Cruz Biotechnology) were used.
After permeabilization, cells were incubated for 1 h at room
temperature with the above-mentioned primary antibodies at the
respective dilutions of 1:50 to 1:1,200. To discriminate the exogenous
expression of E2A from the endogenous one, different concentrations of
the anti-E2A antibody were used; endogenous expression of E2A could be
detected by 1:100-diluted antibody, while overexpressed E2A
derived from the exogenous gene was detected by 1:300-diluted antibody.
Immune complexes containing E2A, Twist, Id1, HEB, FGFR3, and p21 were
detected with rhodamine-conjugated anti-rabbit immunoglobulin G (IgG)
(Chemicon), rhodamine-conjugated anti-goat IgG (Santa Cruz
Biotechnology), and fluorescein isothiocyanate (FITC)-conjugated
anti-mouse IgG (Chemicon). DNA in nuclei was detected with 4',
6'-diamidino-2-phenylindole (DAPI). DNA synthesis was determined by
measuring the 1-h uptake of thymidine analog bromodeoxyuridine (BrdU).
After additional fixation in PBS and DNA denaturation in 2 N HCl, BrdU
was detected using a commercial kit (Boehringer) according to the
manufacturer's instructions, except that a FITC-conjugated antimouse
antibody was substituted in the secondary-antibody step. In the
quantitative analysis, a minimum of 150 positive cells were evaluated
in each transfection. Cells were examined with an Olympus fluorescence
microscope (BX-FLA) or a Zeiss confocal laser-scanning fluorescence
microscope (LSM510UV). The intensity of fluorescence was quantified by
image analyzing computer software NIH Image.
Western blotting.
Cell extracts were prepared by
trichloroacetic acid precipitation as described previously
(51). Proteins were separated by electrophoresis with a
10% acrylamide gel and then analyzed by immunoblotting. Antibodies
were detected using the ECL method (Amersham Life Science).
Immunohistochemistry.
Whole heads of mice at embryonic day
15 were fixed overnight in 4% paraformaldehyde. Sections were prepared
as described previously (20). Tissue sections were stained
with a rabbit polyclonal antibody raised against E2A, HEB, or FGFR3 and
then incubated in biotinylated goat anti-rabbit IgG (Vector
Laboratories). Immunostains were visualized by using a peroxidase
substrate system (Vectastain-elite ABC kit; Vector). Irrelevant rabbit
IgG was used for control experiments. After immunostaining, sections
were counterstained by immersion in 0.5% methyl green in 0.1 M sodium
acetate solution (pH 4.0) and then observed under a light microscope.
ALP activity assay.
Alkaline phosphatase (ALP) activity in
cell supernatants was assayed as outlined in detail previously
(6). Briefly, at the end of the culture periods, the cells
were washed with PBS and scraped into 10 mM Tris-HCl (pH 7.5)-0.5 mM
MgCl2-0.1% Triton X-100. The ALP activity in thawed and
sonicated samples was measured using an ALP diagnostic kit (Sigma;
104-LS). Absorbance at 410 nm was read, and the enzyme activity was
calculated. Protein concentrations were determined with the Bio-Rad
protein assay kit. ALP specific activity was calculated as nanomoles of
p-nitrophenylphosphate per microgram of protein.
 |
RESULTS |
Cell cycle arrest and p21 induction in differentiating MG63
cells.
MG63 cells used in the present study are p53 deficient
(9) and retain common features of normal human
osteoblasts, such as the ability to differentiate in culture by serum
starvation with 1,25-(OH)2D3, an active form of
vitamin D3 (8). First, we investigated how
serum starvation and 1,25-(OH)2D3 influence cell cycle arrest of MG63 cells. MG63 cells, when cultured in medium
with 0.1% FBS for 72 h, showed a great reduction in the proportion of cells in S and G2/M phases (from 33 to 7%)
(Table 1; Fig.
1A). This result indicates that low-serum
culture induces G1 arrest of the cell cycle preceding
differentiation of MG63 cells. The arrest was accelerated by the
addition of 1,25-(OH)2D3 (Table 1).

View larger version (54K):
[in this window]
[in a new window]
|
FIG. 1.
Effects of serum starvation on cell cycle arrest and p21
expression in MG63 cells. (A) G1 arrest by serum
starvation. MG63 cells were cultured in DMEM containing 10% FBS (a) or
0.1% FBS (b) for 48 h and analyzed for their DNA content by flow
cytometry. (B) Activation of p21 promoter by serum starvation. MG63
cells were transfected with 2.5 µg of p21-luc, cultured in DMEM
containing either 10, 2, or 0.1% FBS for 48 h, and collected for
luciferase assay. Luciferase activity is expressed as fold increase
over that for cells cultured in DMEM containing 10% FBS. (C)
Inhibition of cell growth by p21 as measured by BrdU incorporation.
MG63 cells were transfected with pCMV-p21 and pCMV- -gal plasmids and
maintained in DMEM containing 10% FBS for 48 h. BrdU was added
1 h before fixation. Arrowheads, positions corresponding to cells.
The cells were stained for -Gal (a), BrdU (b), and DNA (c). DAPI was
used for counterstaining to visualize the nucleus. Scale bar, 20 µm.
|
|
To gain insight into the molecular mechanism of G
1 arrest,
we examined whether low-serum culture induced expression of p21.
Culture in low-serum medium induced expression of endogenous p21
in
nuclei of MG63 cells (Fig.
2A, a and b),
suggesting that induction
of the
p21 gene is involved in
cell cycle arrest induced by low-serum
culture. To monitor the promoter
activity of the
p21 gene, the
reporter plasmid (p21-luc)
carrying the 2.4-kb fragment encompassing
the p21 promoter region was
transfected into MG63 cells. Then
the cells were cultured for 48 h
in medium with 10, 2, or 0.1%
FBS, and luciferase activity of cell
lysates was determined. A
slight increase (approximately twofold) in
luciferase activity
was seen by culture in medium with 2% FBS compared
with that in
medium with 10% FBS; culture in medium with 0.1% FBS
greatly enhanced
luciferase activity by up to six-to eightfold (Fig.
1B). These
results indicate that serum starvation induces activation of
the
p21 gene promoter.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 2.
Effects of serum starvation on expression of p21, E2A,
Twist, and Id1 in MG63 cells. (A) Proliferating MG63 cells in DMEM
containing 10% FBS (a, c, e, and g) and G1-arrested MG63
cells in DMEM containing 0.1% FBS (b, d, f, and h) were stained with
antibodies for p21 (fluorescein; a and b), E2A (rhodamine; c and d),
Twist (rhodamine; e and f), and Id1 (rhodamine; g and h) and observed
under a fluorescence microscope. Scale bar, 20 µm. (B) MG63 cells
with (+) or without ( ) the E12-expressing plasmid were cultured in
indicated concentrations of FBS. Equal amounts of whole-cell extracts
were analyzed by Western blotting with antibodies against E2A and
-tubulin, Lane +, expression of E12 in cells exogenously
transfected.
|
|
We directly tested if p21 could induce cell cycle arrest in MG63 cells.
MG63 cells were transfected with an expression plasmid
encoding p21 as
well as the

-Gal expression vector and examined
for BrdU
incorporation by immunostaining. The incorporation of
BrdU was impaired
in 95.2% of p21-positive MG63 cells cultured
in high serum (Fig.
1C),
supporting a close link between p21 induction
and cell cycle arrest in
MG63 cells. Importantly, both cell cycle
arrest and p21 induction by
serum starvation are independent of
p53 in MG63
cells.
Activation of the p21 promoter by ectopic E2A.
To determine
whether E2A proteins play a part in growth arrest of MG63 cells, we
examined the expression of endogenous E2A proteins. Our investigation
revealed that E2A was present in nuclei of MG63 cells cultured in high
serum (10% FBS). Low-serum culture (0.1% FBS) enhanced the expression
of E2A (Fig. 2A, c and d). Western blot analysis demonstrated that the
average level of E2A expression in MG63 cells cultured in low serum was
significantly higher than that in the cells cultured in high serum
(Fig. 2B). It should be noted that induction of endogenous p21
expression paralleled the enhanced expression of endogenous E2A (Fig.
2A, a to d).
To determine whether E2A proteins regulate the expression of p21, we
examined the effects of the
E2A gene products, E12 and
E47,
on p21 promoter activity in MG63 cells. MG63 cells were cotransfected
with p21-luc and an E2A expression plasmid (pCMV-E12 or pCMV-E47),
and
luciferase activities were determined after 48 h of culture.
Overexpression of E12 induced activation of the p21 promoter up
to
400-fold in an E12 dose-dependent manner (Fig.
3A). The E12
N-terminal deletion mutant
(aa 508 to 654; del E12) lacking the
transcription activation domain
(
1) failed to induce p21 promoter
activation (Fig.
3A).
Similarly, the p21 promoter was activated
by the ectopic expression of
E47, although the magnitude of activation
was lower than that of E12.
Additive effects of E12 with E47 were
not evident (Fig.
3A). These
results demonstrate that the
E2A products, E12 and E47,
induce p21 promoter activity in MG63 cells.

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 3.
Activation of p21 promoter by E12 and E47 independent of
p53. (A) Transcriptional activation of p21 promoter by E12 and E47.
MG63 cells were cotransfected with 2.0 µg of the p21-luc reporter
plasmid in combination with pCMV-E12, pCMV-E47, or pCMV-del E12
( 1-507). The cells were cultured in DMEM containing 2% FBS for
48 h and collected for luciferase assay. Luciferase activity
mediated by pcDNA3 is arbitrarily set at 1. (B) Schematic diagram of
luc reporter constructs. The 2.4-kb promoter sequence of the
p21 gene (solid line) was cloned at the site upstream of the
luciferase gene in p21-luc. Possible binding sites for E2A (inverted
triangles) and p53 (boxes) in the promoter are shown. Dashed lines,
internal deletions. (C) Two micrograms of p21 promoter deletion mutant
reporter plasmids with or without the E12 or E47 expression plasmid (2 µg) along with the pCMV- -gal plasmid was transfected into MG63
cells. The cells were cultured in DMEM containing 2% FBS for 48 h
and collected for luciferase assay. Luciferase activities were
normalized against -Gal activities. Activities relative to that
mediated by the empty pcDNA3 are shown.
|
|
The
p21 gene is shown to have seven putative E2A-binding
sequences (designated E1 to E7) spreading over the 2.4-kb sequence
upstream of the transcriptional initiation site (Fig.
3B). These
binding sequences are expected to mediate the E2A-dependent activation
of the p21 promoter. To examine this assumption, truncated fragments
containing E2A-binding sites were linked to the luc reporter plasmids
and tested for their ability to respond to E2A in MG63 cells.
A
profound reduction in E2A responsiveness was seen in a mutant
carrying
only three proximal E2A-binding sequences (E1 to E3)
(Fig.
3C). Our
results suggest the involvement of multiple elements
in the p21
promoter region in E2A-induced activation of
p21 gene
transcription.
Endogenous p21 induction and repression of BrdU incorporation by
ectopic E12 expression.
We further tested if E12 could stimulate
expression of the endogenous p21 gene. MG63 cells were
transfected with pCMV-E12 and examined for p21 expression by
immunostaining. Upon introduction of E12, endogenous p21 expression was
induced in cells expressing high levels of E12 even when cultured in
high serum (Fig. 4A; Table
2). These observations strongly support a
close link between p21 induction and E12 expression in MG63 cells (Fig.
2). The incorporation of BrdU, conversely, was decreased in
E12-positive MG63 cells cultured in high serum (Fig. 4B; Table 2).
Similar experiments were carried out by introduction of
-Gal
expression vector pCMV-
-gal in addition to E12 expression vector
pCMV-E12 to identify cells transfected. Cells expressing
-Gal
produced p21 with E12 expression at high levels and were impaired in
incorporation of BrdU (data not shown). Upon introduction of
pCMV-
-gal with a control empty vector, neither endogenous p21
induction nor inhibition of incorporation of BrdU was observed (data
not shown). No appreciable induction of p21 was seen, even in MG63
cells expressing E12, when the antisense p21 sequence was overexpressed
(Fig. 4C). In addition, introduction of the p21 antisense sequence
inhibited E12-mediated cell cycle attenuation; all cells expressing E12
in Fig. 4D were BrdU positive, unlike cells expressing E12 in Fig. 4B.
The proportion of E12-positive MG63 cells expressing p21 was
approximately equivalent to that of cells incapable of synthesizing new
DNA (Table 2). The forced expression of E12 thus presumably causes MG63
cells to arrest at G1 phase through the induction of p21.

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 4.
Effects of E12 on endogenous p21 expression and BrdU
incorporation in MG63 cells. (A) Activation of endogenous p21 by E12
overexpression. MG63 cells were transfected with pCMV-E12 and
maintained in DMEM containing 10% FBS for 72 h. The cells were
fixed and stained for E12 (rhodamine; a), p21 (fluorescein; b), and DNA
(DAPI; c). DAPI was used for counterstaining to visualize the nucleus.
Arrowheads, cells transfected with E12. (B) Effects of E12 on cell
proliferation. MG63 cells were treated by the same procedure as for
panel A. BrdU was added 1 h before fixation. Arrowheads, positions
corresponding to cells. The cells were stained for E12 (rhodamine; a),
BrdU (fluorescein; b), and DNA (DAPI; c). (C) Impairment of
E12-dependent p21 induction by the p21 antisense plasmid. MG63 cells
were transfected with pCMV-E12 and an antisense p21 construct
(pCMV-p21as) and maintained in DMEM containing 10% FBS for 72 h.
The cells were fixed and stained for E12 (rhodamine; a), p21
(fluorescein; b), and DNA (DAPI; c). Arrowheads, cells expressing E12.
(D) Impairment of E12-mediated cell cycle attenuation by the p21
antisense plasmid. MG63 cells were treated by the same procedure as for
panel C. BrdU was added 1 h before fixation. Arrowheads, positions
corresponding to cells. The cells were stained for E12 (rhodamine; a),
BrdU (fluorescein; b), and DNA (DAPI; c). Scale bar, 20 µm.
|
|
Transcriptional inhibition of the p21 gene by Twist and
Ids.
Twist has been shown to interact with E12 (24,
62) and to be expressed in early preosteoblasts
(55). We therefore examined by immunostaining with a
polyclonal antibody raised against the amino terminus of Twist whether
Twist was expressed in MG63 cells. Twist was predominantly present in
nuclei of MG63 cells cultured in medium containing either 2 (data not
shown) or 10% FBS (Fig. 2A, e). Interestingly, we found a peculiar
localization of Twist in serum-starved MG63 cells; it was mainly
localized in the cytoplasm with a granular appearance and was weakly
positive in nuclei (Fig. 2A, f). Similar results were obtained using a
polyclonal antibody raised against the carboxyl terminus of Twist (data
not shown).
To further analyze the biological significance of the interaction of
Twist with E2A for p21 induction in MG63 cells, we tested
the role of
Twist in E2A-dependent activation of p21 transcription.
When p21-luc
was transfected along with the Twist expression vector,
a great
reduction in luciferase activity in both E12- and E47-containing
cells
was observed (Fig.
5A and B), indicating
antagonistic effects
of Twist on E2A-induced transcriptional
activation. Some patients
with Saethre-Chotzen syndrome have mutations
in the
TWIST gene
(
17,
28). A nonsense mutation
(Y103X) found in a patient was
examined for its effect on E2A-induced
p21 activation. Unlike
the wild type, the Twist mutant failed to
inhibit p21 promoter
activation in response to E2A (Fig.
5A and B). The
inhibitory
effect of Twist on E12-dependent p21 promoter activation was
dose
dependent (Fig.
5C). We similarly attempted to determine whether
exogenous Twist suppressed the p21 transcriptional activation
induced
by serum starvation. MG63 cells were transfected with
or without the
Twist expression vector along with p21-luc and
then cultured in medium
containing either 0.1, 2, or 10% FBS.
As expected, the exogenous
expression of Twist suppressed the
stimulatory effect of low-serum
culture on p21-luc expression,
while the Twist (Y103X) mutant had
little, if any, effect on low-serum-mediated
p21 promoter activation
(Fig.
5D).

View larger version (39K):
[in this window]
[in a new window]
|
FIG. 5.
Effects of Twist, Id1, Id2, and CBP on E2A-dependent
transactivation of p21. (A) Inhibition of E12-dependent transactivation
of p21 by Twist, Id1, and Id2. MG63 cells were cotransfected with 2.5 µg of p21-luc in combination with 2.0 µg of either pCMV-E12,
pCMV-Twist, pCMV-Twist (Y103X), pCMV-Id1, or pCMV-Id2. The cells were
cultured in DMEM containing 2% FBS for 48 h and collected for
luciferase assay. Activation mediated by pcDNA3 is arbitrarily set at
1. (B) Inhibition of E47-dependent transactivation of p21 by Twist,
Id1, and Id2. MG63 cells were cotransfected as for panel A except for
pCMV-E12, which was replaced with 2.0 µg of pCMV-E47. (C)
CBP-mediated suppression of inhibition of E12-dependent p21
transcription by Twist. MG63 cells were cotransfected with 1.0 µg of
p21-luc and 0.25 µg of either pcDNA3 or pCMV-E12. The cells were
cultured in DMEM containing 2% FBS for 48 h and collected for
luciferase assay. Activation mediated by pcDNA3 is arbitrarily set at
1. (D) Twist-mediated inhibition of p21 gene expression induced by
serum starvation. MG63 cells were transfected with 2.5 µg of p21-luc
and 2.5 µg of pCMV-Twist or pCMV-Twist (Y103X). The cells were
cultured in DMEM containing either 10, 2, or 0.1% FBS for 48 h
and collected for luciferase assay. Luciferase activity is expressed as
fold increase over that for vehicle-transfected cells cultured in DMEM
containing 10% FBS. Empty vector pcDNA3 was included to adjust DNA
amounts.
|
|
Id proteins are dominant-negative-type HLH molecules which contain
functional HLH dimerization motifs but which lack the DNA-binding
basic
region (
4). Id1 is expressed in early preosteoblasts,
similar to Twist (
39,
55). Our investigation revealed that
Id1 was present in the nuclei of MG63 cells cultured in high serum
(10% FBS) and low serum (0.1% FBS) (Fig.
2A, g and h). Therefore,
the
effects of expression of Id proteins, in addition to Twist,
with
respect to p21 promoter activation were examined. Both Id1
and Id2
reduced luciferase activities driven by the p21 promoter
in response to
E12 and E47 (Fig.
5A and B). The inhibitory levels
achieved by Id1 and
Id2 expression were equivalent to those achieved
by Twist expression.
These results are compatible with the report
that overexpression of Id1
in NIH 3T3 cells accelerates cell growth
and inhibits p21 expression
(
52). Ids have been shown to act
as dominant-negative
antagonists of other bHLH transcription factors
(
48,
52),
but the effects of Ids on Twist function are not
known. We thus
investigated how Id expression influenced the function
of Twist. The
inhibition of E2A-dependent p21 promoter activation
by Twist was
further enhanced by addition of either Id1 or Id2
(Fig.
5A and B),
suggesting that Twist, Id1, and Id2 inhibit p21
expression in a
cooperative
manner.
Inhibition of endogenous p21 induction by ectopic Twist and
Ids.
We further tested if Twist and Id proteins could inhibit
expression of the endogenous p21 gene. MG63 cells were
transfected with expression plasmids for E12 and Twist and then
examined for p21 expression by immunostaining. Upon introduction of
E12, endogenous p21 expression was induced in cells expressing high
levels of E12 (Fig. 4A). Overexpression of Twist abolished the
endogenous p21 expression induced by E12 (Fig.
6A and Table 3). Interestingly, overexpression of Id1 or Id2 showed little effect on E12-dependent endogenous p21 expression (Fig. 6B and C and Table 3), in contrast to
the profound inhibition of the p21 promoter in reporter plasmids (Fig.
5A and B).

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 6.
Inhibition of E12-dependent p21 induction by Twist and
Ids overexpression. MG63 cells were transfected with pCMV-E12 and
either pCMV-Twist (A), pCMV-Id1 (B), or pCMV-Id2 (C). DNA amounts used
for transfection were adjusted by empty vectors. The cells were
maintained in DMEM containing 10% FBS for 72 h. The cells were
fixed and stained for E12 (rhodamine; a), p21 (fluorescein; b), and DNA
(DAPI; c). Arrowheads, cells expressing E12. Scale bar, 20 µm.
|
|
Competition of E12-dependent transcriptional activity between CBP
and Twist.
The coactivator p300/CBP harboring histone
acetyltransferase (HAT) activity has been shown to interact with E12
(16). HAT activity is thought to be important for
decondensing the chromatin and facilitating the binding of the
RNA polymerase II transcription complex to core promoters (2,
44). To analyze the functional implications of the interactions
between E12 and the HAT coactivator, we studied the effects of CBP on
E12-dependent transcriptional activation of the p21 gene.
Overexpression of CBP significantly enhanced the E12-mediated
transactivation of the p21 promoter in the absence of Twist (Fig. 5C).
Twist-induced inhibition of p21 promoter activation in response to E12
was overcome by CBP in a dose-dependent manner (Fig. 5C). Taken
together, these findings support the view that CBP acts as a
coactivator of the E12-mediated transcription of the p21 promoter and
suggest that Twist suppresses transcriptional activity conferred by a
combination of E12 and CBP.
Transcriptional regulation of the FGFR3 gene by E2A,
Twist, Ids, and CBP.
We were interested in investigating the
transcriptional regulatory mechanism that involves E2A, Twist, and Ids
in osteoblast differentiation beyond cell cycle arrest. Thus these
molecules were tested for their effects on expression of the
FGFR3 gene. FGFR3 is expressed in differentiating
osteoblasts at the osteogenic front (55), presumably
leading to the upregulation of genes related to osteoblast
differentiation (10). MG63 cells were cotransfected with
luciferase reporter construct FGFR3-luc containing the 1.5-kb promoter
sequence of the FGFR3 gene, along with one of E2A expression
vectors pCMV-E12 and pCMV-E47. Overexpression of either E12 or E47
activated the FGFR3 promoter in a dose-dependent manner (Fig.
7A). We searched potential sequences for
E2A binding in the FGFR3 gene promoter and found six
candidates spreading over the 1.5-kb sequence upstream of the
transcriptional initiation site (Fig. 7B). To examine whether these
binding sequences mediate the E2A-dependent activation of the FGFR3
promoter, 5'-end-truncated fragments of the FGFR3 promoter were linked
to the luc reporter plasmids and tested for their ability to respond to
E2A in MG63 cells. All mutant fragments, even those lacking any
putative E2A-binding sites, were found to be activated as highly as the
wild type (Fig. 7C).

View larger version (40K):
[in this window]
[in a new window]
|
FIG. 7.
Effects of E2A, Twist, Id1, Id2, and CBP on FGFR3
transcription in MG63 cells. (A) Transcriptional activation of the
FGFR3 promoter by E12 and E47. MG63 cells were cotransfected with 2.5 µg of the FGFR3-luc reporter plasmid along with pCMV-E12 or pCMV-E47.
Cells were harvested 48 h after transfection and then assayed for
their luciferase activities. (B) Schematic diagram of luc reporter
constructs. The 1.5-kb promoter sequence of the FGFR3 gene (solid line)
was cloned at the site upstream of the luciferase gene in FGFR3-luc.
Possible binding sites for E2A (inverted triangles) in the promoter are
shown. (C) Two micrograms of FGFR3 promoter deletion mutant reporter
plasmids with or without the E47 expression plasmid (2 µg) along with
the pCMV- -gal plasmid was transfected into MG63 cells, and
luciferase assays were performed. Luciferase activities were normalized
against -Gal activities. Activities relative to that mediated by the
empty pcDNA3 are shown. (D) Inhibition of E2A-dependent transactivation
of FGFR3 by Twist, Id1, and Id2. MG63 cells were cotransfected with 2.5 µg of p21-luc in combination with 2.0 µg of pCMV-E12, pCMV-E47,
pCMV-Twist, pCMV-Twist (Y103X), pCMV-Id1, and pCMV-Id2. The cells were
harvested 48 h after transfection and then assayed for reporter
gene expression. (E) CBP-mediated suppression of inhibition of
E12-dependent FGFR3 transcription by Twist. MG63 cells were
cotransfected with 1.0 µg of FGFR3-luc and 0.25 µg of either pcDNA3
or the pCMV-E12 expression vector. Activation mediated by pcDNA3 is
arbitrarily set at 1. (F) Additive effect of E2A and
1,25-(OH)2D3 on FGFR3 expression. MG63 cells
were transfected with 2.5 µg of FGFR3-luc and 2.5 µg of pCMV-E12.
The cells were cultured in DMEM containing either 10, 2, or 0.1% FBS
with or without 1,25-(OH)2D3 for 48 h and
collected for luciferase assay. Luciferase activity is expressed as
fold increase over that for vehicle-transfected cells cultured in DMEM
containing 10% FBS. DNA amounts were adjusted by empty vectors.
|
|
We next tested the role of Twist, Id1, and Id2 in E2A-dependent
activation of FGFR3 transcription. A reduction in luciferase
activity
from FGFR3-luc was observed by expression of either Twist,
Id1, or Id2,
while no significant change was induced by expression
of the Twist
(Y103X) mutant (Fig.
7D). Twist-induced inhibition
of FGFR3 promoter
activation in response to E12 was overcome by
CBP in a dose-dependent
manner (Fig.
7E). These results demonstrate
that FGFR3 is a
transcriptional target of E2A, and this expression
could be regulated
by a coordination of Twist, Ids, and CBP, similar
to what was found for
the
p21 gene.
Expression of E2A and FGFR3 during calvarial bone development in
vivo.
To address the implications of E2A and FGFR3 for in vivo
calvarial bone development, we examined the localization of the two molecules in calvarial bone tissue of mouse fetus by immunostaining. An
examination of fetuses at embryonic day 15 showed that E2A was
expressed at bordering areas of condensing calvarial mesenchyme just
lateral to the temporal cartilage (Fig.
8A, a and b). Expression of FGFR3 was
found at the same sites (Fig. 8A, c). Ubiquitous bHLH factor HEB was
also expressed in the developing calvarial bones (data not shown). The
border positive for E2A, HEB, and FGFR3 is known to be an osteogenic
area where osteoprogenitors differentiate into the parietal bones
through osteoblasts (55). Interestingly, E2A and FGFR3
were also expressed in differentiated neurons of the cortical plate,
whereas very low levels of FGFR3 and E2A were detected in
undifferentiated cells of the ventricular zone (Fig. 8A). These
findings strongly support the possibility that bHLH molecules E2A and
presumably HEB play roles in regulating the expression of FGFR3.

View larger version (57K):
[in this window]
[in a new window]
|
FIG. 8.
Osteoblast differentiation in vivo and in vitro. (A) E2A
and FGFR3 expression in the developing calvarial bones. Frontal
sections were stained with antibodies for E2A (a and b) and FGFR3 (c).
Solid arrowheads (a to c) and open arrowhead (a), cortical plate and
the ventricular zone, respectively. The region between arrows (b and c)
indicate parietal bones with osteoblast differentiation. Box (a),
magnified area shown in panels b and c. cc, cerebral cortex; pb,
parietal bone; tc, temporal cartilages; ep, epithelium. Scale bar, 200 µm. (B) Activation of endogenous FGFR3 by E47 overexpression. MG63
cells were transfected with pCMV-E47 and pnGFP and maintained in DMEM
containing 2% FBS for 72 h. The cells were fixed and stained for
FGFR3 (rhodamine; b) and DNA (DAPI; c). pnGFP (fluorescein; a) was used
as a marker to visualize the transfected cells. DAPI was used for
counterstaining to visualize the nucleus. Arrowheads, cells transfected
with E47. Scale bar, 20 µm. (C) Effects of
1,25-(OH)2D3 with serum starvation on
expression of endogenous FGFR3 in MG63 cells. Proliferating MG63 cells
in DMEM containing 10% FBS (a) and G1-arrested MG63 cells
in DMEM containing 0.1% FBS with 1,25-(OH)2D3
(b) were stained with antibodies for FGFR3 and observed under a
confocal laser microscope. Scale bar, 20 µm. (D) ALP activity in MG63
cells. Cells were transfected with either pCMV-E12, pCMV-Twist, or
empty vector and cultured with or without
1,25-(OH)2D3 for 96 h. The cells were
harvested, and cell extracts were prepared for determining ALP
activities. Values are means with standard errors of three independent
experiments.
|
|
Endogenous FGFR3 induction by ectopic E47 expression.
We
further tested if E47 could stimulate expression of the endogenous
FGFR3 gene. MG63 cells were cotransfected with pCMV-E47 and
pnGFP and examined for FGFR3 expression by immunostaining. Upon
introduction of E47, endogenous FGFR3 expression in cells cultured in
2% FBS was greatly enhanced (Fig. 8B). Quantitative analysis of the
integrated density indicated that MG63 cells transfected with E47
expressed endogenous FGFR3 at a level approximately twofold that at
which it was expressed in untransfected cells. These observations are
consistent with the reporter assay (Fig. 7A) and strongly support the
implication of E47 in FGFR3 promoter activation in MG63 cells.
Effects of 1,25-(OH)2D3 on expression of
p21 and FGFR3.
1,25-(OH)2D3 stimulates
MG63 cells to differentiate into cells with osteoblastic phenotypes
under low-serum conditions (6). We therefore examined the
effects of 1,25-(OH)2D3 on the bHLH-regulated transcriptional regulatory network. Low-serum-induced G1
cell cycle arrest of MG63 cells was enhanced by the addition of
1,25-(OH)2D3 (Table 1). The p21 promoter was
slightly activated (approximately 1.5-fold) in response to
1,25-(OH)2D3 with 2% FBS when the vitamin D3 receptor was introduced into the MG63 cells (data not shown).
The influence of 1,25-(OH)
2D
3 on the expression
of FGFR3 in MG63 cells further examined.
1,25-(OH)
2D
3 with 2% FBS showed little
effect
(approximately 1.8-fold enhancement) on E12-induced activation
of the
FGFR3 promoter (Fig.
7F). Western blot analysis indicated
that amounts
of E2A molecules did not appear to be changed greatly
in response to
1,25-(OH)
2D
3 (data not shown). Thus the effects
of 1,25-(OH)
2D
3 and E2A on the FGFR3 promoter
seemed to be independent
and additive (Fig.
7F). The
1,25-(OH)
2D
3 effect was presumably
exerted
through two possible vitamin D response elements in the
FGFR3 promoter
region. We then examined by immunostaining with
a polyclonal antibody
raised against FGFR3 whether FGFR3 was induced
by
1,25-(OH)
2D
3 in low-serum medium.
Immunofluorescence staining
revealed that
1,25-(OH)
2D
3 in low-serum culture profoundly
enhanced
the expression of endogenous FGFR3 in the cytoplasm (Fig.
8C).
However it was hard to see any difference in endogenous FGFR3
expression between 0.1%-serum cultures with and without
1,25-(OH)
2D
3 (data not
shown).
Osteoblast differentiation by bHLH proteins.
We finally wished
to examine the possibility that bHLH-mediated coordination of p21 and
FGFR3 expression induced osteoblast differentiation. This issue was
assessed by examining induction of ALP, which is considered a marker of
the final differentiation of osteoblasts. MG63 cells cultured in low
serum (0.1%) produced a significant amount of ALP (Fig. 8D),
similar to the results of low-serum-induced activation of E2A,
as shown in Fig. 2. No appreciable change between 10 and 2% serum
culture was observed (Fig. 8D). Either addition of
1,25-(OH)2D3 or overexpression of E12 slightly
enhanced expression of ALP in 0.1%-FBS culture; additive effects were
seen when both treatments were done together. Introduction of Twist
into MG63 cells cultured in 0.1% FBS with
1,25-(OH)2D3 remarkably reduced the level of
ALP. These results directly demonstrate the involvement of bHLH
molecules in physiological osteoblast differentiation.
 |
DISCUSSION |
The present study demonstrates that E2A transcription factors (E12
and E47), HLH transcriptional inhibitors (Twist, Id1, and Id2), and
coactivator CBP regulate the expression of the p21 and FGFR3 genes, which are closely associated with cell cycle
arrest and differentiation of osteoblasts, respectively. Cellular
differentiation involves at least two major and distinct steps: (i)
commitment, which irreversibly withdraws proliferating cells from the
cell cycle, and (ii) induction of tissue-specific genes, which promote differentiation resulting in expression of characteristic phenotypes. This is the first report showing the involvement of common
transcriptional regulation in two genes expressed at distinct steps in
the course of osteoblast differentiation. The finding that these
transcription factors are involved in regulation of differentiation
through gene expression related to cell cycle arrest and
tissue-specific gene expression, particularly regulation of the
p21 gene, may be applicable to other cell lineages besides
osteoblasts. This assumption may be supported by observations that MyoD
induces terminal cell cycle arrest during skeletal muscle
differentiation by increasing the expression level of p21
(22) and that Twist inhibits the expression of the
MCK gene by interacting with MyoD (24, 62).
p53 has been shown to be responsible for cell cycle arrest at the
G1 phase through direct induction of the p21
gene (15, 18). In contrast, p53-independent induction of
p21 has been demonstrated in several cell lineages (60,
63). It should be noted that mice that are homozygous for a
targeted disruption of the p53 gene develop normally (14).
There is a paucity of information on p53 expression during
differentiation from preosteoblasts to mature osteocytes via
osteoblasts. Our results show that the p53-deficient osteoblasts remain
arrested in G1 phase when cultured in low-serum medium,
suggesting the possibility that cell cycle withdrawal and induction of
p21 occur independently of p53 in osteoblasts. p53 may act
synergistically with E2A, to activate p21 expression in wild-type
cells. Alternatively, regulation of p21 gene expression by
p53 may be independent of regulation by E2A. HEB, a ubiquitous bHLH
factor with biochemical and functional properties similar to those of
E2A (29), was expressed in the developing calvarial bones
and the nuclei of MG63 cells (data not shown). These results may
support the observation that E2A-deficient mice do not show bone
formation defects (71); these transcription factors
presumably compensate each other.
This study presents several aspects of the mechanism by which low-serum
culture induces p21. An increase in the amount of E2A in the nucleus
due to low-serum culture (Fig. 2A, c and d, and B) is, at least in
part, responsible for induction of the p21 gene. E47 has
also been reported to be increased during erythroid differentiation by
the addition of stem cell factor (70). The p21 promoter
region contained multiple binding sites for p53 and E2A (Fig. 3B), and
two proximal E2A-binding sites (E1 and E2) were demonstrated to be able
to mediate E47-dependent activation in HeLa cells (52).
Our deletion analysis of the p21 promoter indicates that the two
proximal E2A-binding sites are not sufficient for E47-dependent
activation of the promoter in osteoblast cell line MG63 (Fig. 3C). The
discrepancy in results between the two groups may be due to differences
in the experimental systems, including the different cell lines used.
It is possible that E2A activates the p21 promoter indirectly. Deletion
analysis of the FGFR3 promoter also indicates that the putative E2A
binding sites are not sufficient for E47-dependent activation of the
promoter in MG63 cells (Fig. 7C). Further studies on the implications
of bHLH proteins in these promoters would be useful for our
understanding of osteoblastic differentiation and Saethre-Chotzen syndrome.
We demonstrate in this study that overexpression of coactivator CBP
transcriptionally enhances E12-dependent activation of the p21 promoter
in osteoblasts (Fig. 5C). This result is similar to previous reports
that p300/CBP is required for the expression of cell cycle inhibitors
p21 and p27 in F9 cells (31). The induction of p21
expression in keratinocyte differentiation is dependent on p300, which
alone has been shown to be unable to stimulate the p21 promoter to any
significant extent (37). E2A proteins recruit p300/CBP to
activate target genes via nuclear HAT activity (16). HAT
activity seems to play a role in the induction of p21 gene
expression during osteoblast differentiation.
Our results further show that Twist, Id1, and Id2 inhibit transcription
of the p21 gene induced by the combination of E2A and CBP.
Twist and Ids are involved in the suppression of differentiation through inhibition of p21 expression, preventing unnecessary
G1 arrest. We assume that growing cells are inhibited in
expressing p21 presumably by formation of a multicomponent complex
consisting of an activator complex of E2A with p300/CBP and the
inhibitor Twist. Physical interactions between E2A and E2A
(40), E2A and Twist (24, 62), E2A and Ids
(25), E2A and p300/CBP (16, 54), and Twist
and p300/CBP (23) have been reported. In particular, overexpression of Twist completely suppressed E12-dependent induction of endogenous p21 expression (Fig. 6A and Table 3), while
overexpression of Ids was less effective in suppression of endogenous
p21 expression in response to E12 (Fig. 6B and C and Table
3). Ids may be present in
insufficient amounts in our experiment. Alternatively, the difference
may be due to the functional properties of Twist and Ids. Very recently
Twist has been reported to bind directly to p300/CBP and
p300/CBP-associated factor through two independent HAT domains,
resulting in inhibition of HAT activities (23). HAT
activity is important for decondensing the chromatin (2, 44), changing the accessibility of the transcription machinery (67). In contrast, it has not been reported that Ids have
the ability to inhibit HAT activities. Transcription from ectopic reporter plasmids lacking a condensed chromatin structure is inhibited by Ids; however Ids ineffectively inhibit the endogenous p21 gene promoter with the chromatin structure. These ideas might be consistent with the observation that Saethre-Chotzen syndrome results from mutations of the TWIST gene; nevertheless no
mutations in the Id genes of patients with
Saethre-Chotzen syndrome have been found so far, even though both
molecules are expressed in early preosteoblasts (55). Our
observations firmly imply that the inhibition of HAT activities may be
a mechanism underlying the Twist-mediated inhibition of the
E2A-CBP-dependent transcription.
Dimerization is essential for bHLH proteins to bind DNA and exert
transcriptional activity (34), and, in general, the
ubiquitously expressed E2A proteins heterodimerize with tissue-specific
bHLH proteins such as MyoD and myogenin in myoblasts (34,
68), LYL1 in T cells (38), and eHAND in
trophoblasts (12). Cell-type-specific bHLH proteins can
directly interact with the p300/CBP HAT (16, 41, 53, 54,
59) when bound as a heterodimer with an E2A protein. Although
there has been no report concerning bone-specific bHLH factors, it is
interesting to speculate that E2A heterodimerizes with an unidentified
bone-specific bHLH factor. This speculation may be supported by our and
other groups' observations on the transactivation activity of the bHLH
proteins. For example, E12 activates transcriptional activity of the
p21 gene more highly than E47 (Fig. 3A); nevertheless E12 is
shown to efficiently heterodimerize with tissue-specific bHLH factors
and not to homodimerize, unlike E47 (5, 64).
Low-serum culture of MG63 cells induces Twist expression.
Interestingly, we found that, in cells cultured in low-serum medium, the Twist protein is predominantly and characteristically present in
the cytoplasm in a granular pattern, in contrast to nuclear localization of Twist protein in cells cultured in high serum (Fig. 2A,
e and f). bHLH proteins have been shown to be posttranslationally modified in terms of phosphorylation and dephosphorylation (30, 61). Granular localization in the cytoplasm may result from phosphorylation that may be mediated by a kinase activated upon low-serum culture. It has been shown in yeast that phosphorylation alters the localization of bHLH protein Pho4 (45). There
is a possibility that Twist in the cytoplasm blocks nuclear import of
other bHLH factors. The bHLH inhibitor I-mfa binds to MyoD family
members and blocks their nuclear import (32).
Heterodimerization of bHLH proteins has been proposed to take place in
the cytoplasm prior to nuclear import (21). An increase in
the amount of Twist due to low-serum culture may make the effect complete.
Without affecting the expression of genes participating in
proliferation, such as the E2F-1, E2F-2, cyclin E, and myc genes (data
not shown), Twist may make cells remain in an undifferentiated state by
regulating p21 expression, thereby increasing the proliferation rate, and may have a role in the genesis of some tumors. This is
consistent with the fact that enhanced expression of Twist is observed
in rhabdomyosarcomas, which originate from undifferentiated mesenchymal
cells (36).
The present study paves the way for analyzing the molecular etiology of
craniosynostosis. Craniosynostosis syndromes are characterized by early
fusion of cranial sutures, presumably based on an increase in
osteoblast activity as a result of precocious osteoblast
differentiation. Saethre-Chotzen syndrome has been attributed to
mutations of the gene for Twist or FGFR3, and phenotypes in patients
with mutations of TWIST and FGFR3 are
indistinguishable (56). The craniosynostosis induced by a
loss-of-function mutation of TWIST is a
haploinsufficiency phenotype (7). Craniosynostosis
associated with FGFR3 with a Pro250Arg mutation is thought to be
due to a gain-of-function mechanism. Inhibition of transcription by
Twist would thus be greatly significant in determining the timing of
initiation of osteoblast differentiation. Twist inhibits the terminal
differentiation of osteoprogenitors into osteoblasts by inhibiting p21
and FGFR3 expression, while the Twist mutant fails to inhibit p21 and
FGFR3 promoter activation (Fig. 5 and 7D). These observations provide evidence that Twist and FGFR3 are included in the same developmental pathway in osteoblast differentiation (Fig.
9). Mutations in TWIST could
lead to a growth defect of osteoprogenitors in the early fusion of the
cranial suture by decreasing proliferation activity and accelerating
differentiation. Other types of FGFR molecules may also be under the
transcriptional regulation by the HLH inhibitors. In addition, Twist
probably functions as an inhibitor of chondrogenesis by inhibiting
expression of FGFR3, which inhibits cell growth in the cartilaginous
growth plates; expression of Twist and terminal differentiation
markers for chondrocyte precursors are mutually exclusive
(27, 58).

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 9.
Regulation of p21 and FGFR3 expression by E2A, Twist,
Ids, and CBP during osteoblast differentiation. Based on our results,
we propose a regulatory mechanism by which expression of p21 and FGFR3
is controlled by E2A proteins, inhibitory HLH proteins, and coactivator
CBP. E2A proteins are activators for both the p21 and
FGFR3 genes. Twist inhibits the function of the E2A-CBP
complex. The model provides the integrated regulation of the expression
of p21 necessary for G1 arrest of the cell cycle and the
expression of FGFR3 as a signal molecule for maturation of osteoblasts.
Dysfunction of Twist and overactivation of FGFR3 signaling result in
craniosynostosis because of the acceleration of bone differentiation.
Twist alters the expression of FGFR3, thereby providing a direct link
between the Twist and FGFR3 pathways.
|
|
Expression of FGFR3 is reported to be seen in neural crest, limb, and
head mesenchyme as well as bone (19, 33, 43, 49, 69). We
have shown that FGFR3 and E2A are expressed in differentiated neurons,
whereas very low levels of FGFR3 and E2A were detected in
undifferentiated cells of the ventricular zone (Fig. 8A). In addition,
FGFR3 functions in the neuronal differentiation of PC12 cells
(66). Some Saethre-Chotzen syndrome patients show not only
synostosis of the coronal suture but also limb abnormalities (brachydactyly and cutaneous syndactyly), mental retardation, conductive deafness, and cleft plates. These suggest that Twist and
FGFR3 are presumably implicated in the development of the epithelial cells and neurons other than osteoblasts.
However it seems unlikely that all cells expressing p21 express FGFR3.
Indeed we observed that the FGFR3 promoter was not activated in rat
embryonic fibroblasts, in contrast to promoters of the MCK
genes (data not shown). It is intriguing to note that E2A
overexpression induces p21 gene expression to a greater
degree than that of the FGFR3 gene (Fig. 3A versus 7A). We
thus speculate that there is a difference in gene expression between
p21 and FGFR3 in terms of transcriptional regulation.
In a broader context, our study suggests that HLH factors and
coactivator CBP play multiple roles in development via the cell cycle
and differentiation of osteoblasts. The determination of components of
these developmental pathways could lead to the identification of
additional candidate genes for different genetic diseases.
 |
ACKNOWLEDGMENTS |
We thank C. Murre for the E12 and E47 clones, H. Hara for the
Id1, Id2, and del E12 (aa 508 to 654) clones, E. Lees for the cosmid
clone pc385.12 containing the human FGFR3 gene, B. Vogelstein for the p21 promoter, T. Nakajima for the expression
plasmids for CBP, and E. Bingman for the hVDR clones. We are also
indebted to T. Gridley, H. Hara, and H. Funato for critical reading and useful suggestions.
This study was supported in part by Grants-in-Aid for Scientific
Research and Cancer Research from the Ministry of Education, Science,
Sports and Culture of Japan, by a grant from the Core Research for
Evolutional Science and Technology (CREST) of Japan Science and
Technology Corp., and by the Exceptional Research Subsidy from Tokyo
Medical and Dental University.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Human Gene
Sciences Center, Tokyo Medical and Dental University, 1-5-45 Yushima,
Bunkyo-ku, Tokyo 113-8510, Japan. Phone: 81-3-5803-5797. Fax:
81-3-5803-0234. E-mail: naka.gene{at}cmn.tmd.ac.jp.
 |
REFERENCES |
| 1.
|
Aronheim, A.,
R. Shiran,
A. Rosen, and M. D. Walker.
1993.
The E2A gene product contains two separable and functionally distinct transcription activation domains.
Proc. Natl. Acad. Sci. USA
90:8063-8067[Abstract/Free Full Text].
|
| 2.
|
Bannister, A. J., and T. Kouzarides.
1996.
The CBP co-activator is a histone acetyltransferase.
Nature
384:641-643[CrossRef][Medline].
|
| 3.
|
Bate, M.,
E. Rushton, and D. A. Currie.
1991.
Cells with persistent twist expression are the embryonic precursors of adult muscles in Drosophila.
Development
113:79-89[Abstract].
|
| 4.
|
Benezra, R.,
R. L. Davis,
D. Lockshon,
D. L. Turner, and H. Weintraub.
1990.
The protein Id: a negative regulator of helix-loop-helix DNA binding proteins.
Cell
61:49-59[CrossRef][Medline].
|
| 5.
|
Blackwell, T. K., and H. Weintraub.
1990.
Differences and similarities in DNA-binding preferences of MyoD and E2A protein complexes revealed by binding site selection.
Science
250:1104-1110[Abstract/Free Full Text].
|
| 6.
|
Bonewald, L. F.,
M. B. Kester,
Z. Schwartz,
L. D. Swain,
A. Khare,
T. L. Johnson,
R. J. Leach, and B. D. Boyan.
1992.
Effects of combining transforming growth factor b and 1,25-dihydroxyvitamin D3 on differentiation of a human osteosarcoma (MG-63).
J. Biol. Chem.
267:8943-8949[Abstract/Free Full Text].
|
| 7.
|
Bourgeois, P.,
B. A. Bolcato,
J. M. Danse,
Z. A. Bloch,
K. Yoshiba,
C. Stoetzel, and S. F. Perrin.
1998.
The variable expressivity and incomplete penetrance of the twist-null heterozygous mouse phenotype resemble those of human Saethre-Chotzen syndrome.
Hum. Mol. Genet.
7:945-957[Abstract/Free Full Text].
|
| 8.
|
Boyan, B. D.,
Z. Schwartz,
L. F. Bonewald, and L. D. Swain.
1989.
Localization of 1,25-(OH)2D3-responsive alkaline phosphatase in osteoblast-like cells (ROS 17/2.8, MG 63, and MC 3T3) and growth cartilage cells in culture.
J. Biol. Chem.
264:11879-11886[Abstract/Free Full Text].
|
| 9.
|
Chandar, N.,
B. Billig,
J. McMaster, and J. Novak.
1992.
Inactivation of p53 gene in human and murine osteosarcoma cells.
Br. J. Cancer
65:208-214[Medline].
|
| 10.
|
Chen, L.,
R. Adar,
X. Yang,
E. O. Monsonego,
C. Li,
P. V. Hauschka,
A. Yayon, and C. X. Deng.
1999.
Gly369Cys mutation in mouse FGFR3 causes achondroplasia by affecting both chondrogenesis and osteogenesis.
J. Clin. Investig.
104:1517-1525[Medline].
|
| 11.
|
Chrivia, J. C.,
R. P. Kwok,
N. Lamb,
M. Hagiwara,
M. R. Montminy, and R. H. Goodman.
1993.
Phosphorylated CREB binds specifically to the nuclear protein CBP.
Nature
365:855-859[CrossRef][Medline].
|
| 12.
|
Cserjesi, P.,
D. Brown,
G. E. Lyons, and E. N. Olson.
1995.
Expression of the novel basic helix-loop-helix gene eHAND in neural crest derivatives and extraembryonic membranes during mouse development.
Dev. Biol.
170:664-678[CrossRef][Medline].
|
| 13.
|
Datto, M. B.,
Y. Li,
J. F. Panus,
D. J. Howe,
Y. Xiong, and X. F. Wang.
1995.
Transforming growth factor induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism.
Proc. Natl. Acad. Sci. USA
92:5545-5549[Abstract/Free Full Text].
|
| 14.
|
Donehower, L. A.,
M. Harvey,
B. L. Slagle,
M. J. McArthur,
C. A. Montgomery, Jr.,
J. S. Butel, and A. Bradley.
1992.
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.
Nature
356:215-221[CrossRef][Medline].
|
| 15.
|
Dulic, V.,
W. K. Kaufmann,
S. J. Wilson,
T. D. Tlsty,
E. Lees,
J. W. Harper,
S. J. Elledge, and S. I. Reed.
1994.
p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest.
Cell
76:1013-1023[CrossRef][Medline].
|
| 16.
|
Eckner, R.,
T. P. Yao,
E. Oldread, and D. M. Livingston.
1996.
Interaction and functional collaboration of p300/CBP and bHLH proteins in muscle and B-cell differentiation.
Genes Dev.
10:2478-2490[Abstract/Free Full Text].
|
| 17.
|
el-Deiry, W. S.,
T. Tokino,
V. E. Velculescu,
D. B. Levy,
R. Parsons,
J. M. Trent,
D. Lin,
W. E. Mercer,
K. W. Kinzler, and B. Vogelstein.
1993.
WAF1, a potential mediator of p53 tumor suppression.
Cell
75:817-825[CrossRef][Medline].
|
| 18.
|
el Ghouzzi, V.,
M. Le Merrer,
F. Perrin-Schmitt,
E. Lajeunie,
P. Benit,
D. Renier,
P. Bourgeois,
A. L. Bolcato-Bellemin,
A. Munnich, and J. Bonaventure.
1997.
Mutations of the TWIST gene in the Saethre-Chotzen syndrome.
Nat. Genet.
15:42-46[CrossRef][Medline].
|
| 19.
|
Fuchtbauer, E. M.
1995.
Expression of M-twist during postimplantation development of the mouse.
Dev. Dyn.
204:316-322[Medline].
|
| 20.
|
Funato, N.,
K. Moriyama,
M. Saitoh,
Y. Baba,
H. Ichijo, and T. Kuroda.
1998.
Evidence for apoptosis signal-regulating kinase 1 in the regenerating palatal epithelium upon acute injury.
Lab. Investig.
78:477-483[Medline].
|
| 21.
|
Goldfarb, A. N., and K. Lewandowska.
1994.
Nuclear redirection of a cytoplasmic helix-loop-helix protein via heterodimerization with a nuclear localizing partner.
Exp. Cell Res.
214:481-485[CrossRef][Medline].
|
| 22.
|
Halevy, O.,
B. G. Novitch,
D. B. Spicer,
S. X. Skapek,
J. Rhee,
G. J. Hannon,
D. Beach, and A. B. Lassar.
1995.
Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD.
Science
267:1018-1021[Abstract/Free Full Text].
|
| 23.
|
Hamamori, Y.,
V. Sartorelli,
V. Ogryzko,
P. L. Puri,
H. Y. Wu,
J. Y. Wang,
Y. Nakatani, and L. Kedes.
1999.
Regulation of histone acetyltransferases p300 and PCAF by the bHLH protein twist and adenoviral oncoprotein E1A.
Cell
96:405-413[CrossRef][Medline].
|
| 24.
|
Hamamori, Y.,
H. Y. Wu,
V. Sartorelli, and L. Kedes.
1997.
The basic domain of myogenic basic helix-loop-helix (bHLH) proteins is the novel target for direct inhibition by another bHLH protein, Twist.
Mol. Cell. Biol.
17:6563-6573[Abstract].
|
| 25.
|
Hara, E.,
M. Hall, and G. Peters.
1997.
Cdk2-dependent phosphorylation of Id2 modulates activity of E2A-related transcription factors.
EMBO J.
16:332-342[CrossRef][Medline].
|
| 26.
|
Harper, J. W.,
G. R. Adami,
N. Wei,
K. Keyomarsi, and S. J. Elledge.
1993.
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Cell
75:805-816[CrossRef][Medline].
|
| 27.
|
Hebrok, M.,
K. Wertz, and E. M. Fuchtbauer.
1994.
M-twist is an inhibitor of muscle differentiation.
Dev. Biol.
165:537-544[CrossRef][Medline].
|
| 28.
|
Howard, T. D.,
W. A. Paznekas,
E. D. Green,
L. C. Chiang,
N. Ma,
R. I. Ortiz de Luna,
D. C. Garcia,
R. M. Gonzalez,
A. D. Kline, and E. W. Jabs.
1997.
Mutations in TWIST, a basic helix-loop-helix transcription factor, in Saethre-Chotzen syndrome.
Nat. Genet.
15:36-41[CrossRef][Medline].
|
| 29.
|
Hu, J. S.,
E. N. Olson, and R. E. Kingston.
1992.
HEB, a helix-loop-helix protein related to E2A and ITF2 that can modulate the DNA-binding ability of myogenic regulatory factors.
Mol. Cell. Biol.
12:1031-1042[Abstract/Free Full Text].
|
| 30.
|
Johnson, S. E.,
X. Wang,
S. Hardy,
E. J. Taparowsky, and S. F. Konieczny.
1996.
Casein kinase II increases the transcriptional activities of MRF4 and MyoD independently of their direct phosphorylation.
Mol. Cell. Biol.
16:1604-1613[Abstract].
|
| 31.
|
Kawasaki, H.,
R. Eckner,
T. P. Yao,
K. Taira,
R. Chiu,
D. M. Livingston, and K. K. Yokoyama.
1998.
Distinct roles of the co-activators p300 and CBP in retinoic-acid-induced F9-cell differentiation.
Nature
393:284-289[CrossRef][Medline].
|
| 32.
|
Kraut, N.,
L. Snider,
C. M. Chen,
S. J. Tapscott, and M. Groudine.
1998.
Requirement of the mouse I-mfa gene for placental development and skeletal patterning.
EMBO J.
17:6276-6288[CrossRef][Medline].
|
| 33.
|
Kubota, Y., and K. Ito.
2000.
Chemotactic migration of mesencephalic neural crest cells in the mouse.
Dev. Dyn.
217:170-179[CrossRef][Medline].
|
| 34.
|
Lassar, A. B.,
R. L. Davis,
W. E. Wright,
T. Kadesch,
C. Murre,
A. Voronova,
D. Baltimore, and H. Weintraub.
1991.
Functional activity of myogenic HLH proteins requires hetero-oligomerization with E12/E47-like proteins in vivo.
Cell
66:305-315[CrossRef][Medline].
|
| 35.
|
Lee, M. S.,
G. N. Lowe,
D. D. Strong,
J. E. Wergedal, and C. A. Glackin.
1999.
TWIST, a basic helix-loop-helix transcription factor, can regulate the human osteogenic lineage.
J. Cell. Biochem.
75:566-577[CrossRef][Medline].
|
| 36.
|
Maestro, R.,
A. P. Dei Tos,
Y. Hamamori,
S. Krasnokutsky,
V. Sartorelli,
L. Kedes,
C. Doglioni,
D. H. Beach, and G. J. Hannon.
1999.
Twist is a potential oncogene that inhibits apoptosis.
Genes Dev.
13:2207-2217[Abstract/Free Full Text].
|
| 37.
|
Missero, C.,
E. Calautti,
R. Eckner,
J. Chin,
L. H. Tsai,
D. M. Livingston, and G. P. Dotto.
1995.
Involvement of the cell-cycle inhibitor Cip1/WAF1 and the E1A-associated p300 protein in terminal differentiation.
Proc. Natl. Acad. Sci. USA
92:5451-5455[Abstract/Free Full Text].
|
| 38.
|
Miyamoto, A.,
X. Cui,
L. Naumovski, and M. L. Cleary.
1996.
Helix-loop-helix proteins LYL1 and E2a form heterodimeric complexes with distinctive DNA-binding properties in hematolymphoid cells.
Mol. Cell. Biol.
16:2394-2401[Abstract].
|
| 39.
|
Murray, S. S.,
C. A. Glackin,
K. A. Winters,
D. Gazit,
A. J. Kahn, and E. J. Murray.
1992.
Expression of helix-loop-helix regulatory genes during differentiation of mouse osteoblastic cells.
J. Bone Miner. Res.
7:1131-1138[Medline].
|
| 40.
|
Murre, C.,
P. S. McCaw,
H. Vaessin,
M. Caudy,
L. Y. Jan,
Y. N. Jan,
C. V. Cabrera,
J. N. Buskin,
S. D. Hauschka, and A. B. Lassar.
1989.
Interactions between heterologous helix-loop-helix proteins generate complexes that bind specifically to a common DNA sequence.
Cell
58:537-544[CrossRef][Medline].
|
| 41.
|
Mutoh, H.,
F. J. Naya,
M. J. Tsai, and A. B. Leiter.
1998.
The basic helix-loop-helix protein BETA2 interacts with p300 to coordinate differentiation of secretin-expressing enteroendocrine cells.
Genes Dev.
12:820-830[Abstract/Free Full Text].
|
| 42.
|
Nakajima, T.,
A. Fukamizu,
J. Takahashi,
F. H. Gage,
T. Fisher,
J. Blenis, and M. R. Montminy.
1996.
The signal-dependent coactivator CBP is a nuclear target for pp90RSK.
Cell
86:465-474[CrossRef][Medline].
|
| 43.
|
Noji, S.,
E. Koyama,
F. Myokai,
T. Nohno,
H. Ohuchi,
K. Nishikawa, and S. Taniguchi.
1993.
Differential expression of three chick FGF receptor genes, FGFR1, FGFR2 and FGFR3, in limb and feather development.
Prog. Clin. Biol. Res.
383B:645-654.
|
| 44.
|
Ogryzko, V. V.,
R. L. Schiltz,
V. Russanova,
B. H. Howard, and Y. Nakatani.
1996.
The transcriptional coactivators p300 and CBP are histone acetyltransferases.
Cell
87:953-959[CrossRef][Medline].
|
| 45.
|
O'Neill, E. M.,
A. Kaffman,
E. R. Jolly, and E. K. O'Shea.
1996.
Regulation of PHO4 nuclear localization by the PHO80-PHO85 cyclin-CDK complex.
Science
271:209-212[Abstract].
|
| 46.
|
Parker, S. B.,
G. Eichele,
P. Zhang,
A. Rawls,
A. T. Sands,
A. Bradley,
E. N. Olson,
J. W. Harper, and S. J. Elledge.
1995.
p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells.
Science
267:1024-1027[Abstract/Free Full Text].
|
| 47.
|
Perez-Castro, A. V.,
J. Wilson, and M. R. Altherr.
1997.
Genomic organization of the human fibroblast growth factor receptor 3 (FGFR3) gene and comparative sequence analysis with the mouse Fgfr3 gene.
Genomics
41:10-16[CrossRef][Medline].
|
| 48.
|
Pesce, S., and R. Benezra.
1993.
The loop region of the helix-loop-helix protein Id1 is critical for its dominant negative activity.
Mol. Cell. Biol.
13:7874-7880[Abstract/Free Full Text].
|
| 49.
|
Peters, K.,
D. Ornitz,
S. Werner, and L. Williams.
1993.
Unique expression pattern of the FGF receptor 3 gene during mouse organogenesis.
Dev. Biol.
155:423-430[CrossRef][Medline].
|
| 50.
|
Peverali, F. A.,
T. Ramqvist,
R. Saffrich,
R. Pepperkok,
M. V. Barone, and L. Philipson.
1994.
Regulation of G1 progression by E2A and Id helix-loop-helixproteins.
EMBO J.
13:4291-4301[Medline].
|
| 51.
|
Piatti, S.,
T. Bohm,
J. H. Cocker,
J. F. Diffley, and K. Nasmyth.
1996.
Activation of S-phase-promoting CDKs in late G1 defines a "point of no return" after which Cdc6 synthesis cannot promote DNA replication in yeast.
Genes Dev.
10:1516-1531[Abstract/Free Full Text].
|
| 52.
|
Prabhu, S.,
A. Ignatova,
S. T. Park, and X. H. Sun.
1997.
Regulation of the expression of cyclin-dependent kinase inhibitor p21 by E2A and Id proteins.
Mol. Cell. Biol.
17:5888-5896[Abstract].
|
| 53.
|
Puri, P. L.,
M. L. Avantaggiati,
C. Balsano,
N. Sang,
A. Graessmann,
A. Giordano, and M. Levrero.
1997.
p300 is required for MyoD-dependent cell cycle arrest and muscle-specific gene transcription.
EMBO J.
16:369-383[CrossRef][Medline].
|
| 54.
|
Qiu, Y.,
A. Sharma, and R. Stein.
1998.
p300 mediates transcriptional stimulation by the basic helix-loop-helix activators of the insulin gene.
Mol. Cell. Biol.
18:2957-2964[Abstract/Free Full Text].
|
| 55.
|
Rice, D. P.,
T. Aberg,
Y. Chan,
Z. Tang,
P. J. Kettunen,
L. Pakarinen,
R. E. Maxson, and I. Thesleff.
2000.
Integration of FGF and TWIST in calvarial bone and suture development.
Development
127:1845-1855[Abstract].
|
| 56.
|
Rose, C. S.,
P. Patel,
W. Reardon,
S. Malcolm, and R. M. Winter.
1997.
The TWIST gene, although not disrupted in Saethre-Chotzen patients with apparently balanced translocations of 7p21, is mutated in familial and sporadic cases.
Hum. Mol. Genet.
6:1369-1373[Abstract/Free Full Text].
|
| 57.
|
Rose, M., and D. Botstein.
1983.
Construction and use of gene fusions to lacZ ( -galactosidase) that are expressed in yeast.
Methods Enzymol.
101:167-180[Medline].
|
| 58.
|
Sandell, L. J.,
N. Morris,
J. R. Robbins, and M. B. Goldring.
1991.
Alternatively spliced type II procollagen mRNAs define distinct populations of cells during vertebral development: differential expression of the amino-propeptide.
J. Cell Biol.
114:1307-1319[Abstract/Free Full Text].
|
| 59.
|
Sartorelli, V.,
J. Huang,
Y. Hamamori, and L. Kedes.
1997.
Molecular mechanisms of myogenic coactivation by p300: direct interaction with the activation domain of MyoD and with the MADS box of MEF2C.
Mol. Cell. Biol.
17:1010-1026[Abstract].
|
| 60.
|
Sheikh, M. S.,
X. S. Li,
J. C. Chen,
Z. M. Shao,
J. V. Ordonez, and J. A. Fontana.
1994.
Mechanisms of regulation of WAF1/Cip1 gene expression in human breast carcinoma: role of p53-dependent and independent signal transduction pathways.
Oncogene
9:3407-3415[Medline].
|
| 61.
|
Sloan, S. R.,
C. P. Shen,
R. McCarrick-Walmsley, and T. Kadesch.
1996.
Phosphorylation of E47 as a potential determinant of B-cell-specific activity.
Mol. Cell. Biol.
16:6900-6908[Abstract].
|
| 62.
|
Spicer, D. B.,
J. Rhee,
W. L. Cheung, and A. B. Lassar.
1996.
Inhibition of myogenic bHLH and MEF2 transcription factors by the bHLH protein Twist.
Science
272:1476-1480[Abstract].
|
| 63.
|
Steinman, R. A.,
B. Hoffman,
A. Iro,
C. Guillouf,
D. A. Liebermann, and M. E. el-Houseini.
1994.
Induction of p21 (WAF-1/CIP1) during differentiation.
Oncogene
9:3389-3396[Medline].
|
| 64.
|
Sun, X. H., and D. Baltimore.
1991.
An inhibitory domain of E12 transcription factor prevents DNA binding in E12 homodimers but not in E12 heterodimers.
Cell
64:459-470[CrossRef][Medline].
|
| 65.
|
Thisse, B.,
C. Stoetzel,
T. C. Gorostiza, and S. F. Perrin.
1988.
Sequence of the twist gene and nuclear localization of its protein in endomesodermal cells of early Drosophila embryos.
EMBO J.
7:2175-2183[Medline].
|
| 66.
|
Thompson, L. M.,
S. Raffioni,
J. J. Wasmuth, and R. A. Bradshaw.
1997.
Chimeras of the native form or achondroplasia mutant (G375C) of human fibroblast growth factor receptor 3 induce ligand-dependent differentiation of PC12 cells.
Mol. Cell. Biol.
17:4169-4177[Abstract].
|
| 67.
|
Ura, K.,
H. Kurumizaka,
S. Dimitrov,
G. Almouzni, and A. P. Wolffe.
1997.
Histone acetylation: influence on transcription, nucleosome mobility and positioning, and linker histone-dependent transcriptional repression.
EMBO J.
16:2096-2107[CrossRef][Medline].
|
| 68.
|
Weintraub, H.,
R. Davis,
S. Tapscott,
M. Thayer,
M. Krause,
R. Benezra,
T. K. Blackwell,
D. Turner,
R. Rupp, and S. Hollenberg.
1991.
The myoD gene family: nodal point during specification of the muscle cell lineage.
Science
251:761-766[Abstract/Free Full Text].
|
| 69.
|
Wolf, C.,
C. Thisse,
C. Stoetzel,
B. Thisse,
P. Gerlinger, and S. F. Perrin.
1991.
The M-twist gene of Mus is expressed in subsets of mesodermal cells and is closely related to the Xenopus X-twi and the Drosophila twist genes.
Dev. Biol.
143:363-373[CrossRef][Medline].
|
| 70.
|
Zhang, M. Y.,
G. A. Clawson,
N. F. Olivieri,
L. L. Bell,
C. G. Begley, and B. A. Miller.
1997.
Expression of SCL is normal in transfusion-dependent Diamond-Blackfan anemia but other bHLH proteins are deficient.
Blood
90:2068-2074[Abstract/Free Full Text].
|
| 71.
|
Zhuang, Y.,
C. G. Kim,
S. Bartelmez,
P. Cheng,
M. Groudine, and H. Weintraub.
1992.
Helix-loop-helix transcription factors E12 and E47 are not essential for skeletal or cardiac myogenesis, erythropoiesis, chondrogenesis, or neurogenesis.
Proc. Natl. Acad. Sci. USA
89:12132-12136[Abstract/Free Full Text].
|
Molecular and Cellular Biology, November 2001, p. 7416-7428, Vol. 21, No. 21
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.21.7416-7428.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Pedraza, N., Rafel, M., Navarro, I., Encinas, M., Aldea, M., Gallego, C.
(2009). Mixed Lineage Kinase Phosphorylates Transcription Factor E47 and Inhibits TrkB Expression to Link Neuronal Death and Survival Pathways. J. Biol. Chem.
284: 32980-32988
[Abstract]
[Full Text]
-
Funato, N., Chapman, S. L., McKee, M. D., Funato, H., Morris, J. A., Shelton, J. M., Richardson, J. A., Yanagisawa, H.
(2009). Hand2 controls osteoblast differentiation in the branchial arch by inhibiting DNA binding of Runx2. Development
136: 615-625
[Abstract]
[Full Text]
-
Laursen, K. B., Mielke, E., Iannaccone, P., Fuchtbauer, E.-M.
(2007). Mechanism of Transcriptional Activation by the Proto-oncogene Twist1. J. Biol. Chem.
282: 34623-34633
[Abstract]
[Full Text]
-
Wang, M., Gu, C., Qi, T., Tang, W., Wang, L., Wang, S., Zeng, X.
(2007). BAF53 Interacts with p53 and Functions in p53-mediated p21-gene Transcription. J Biochem
142: 613-620
[Abstract]
[Full Text]
-
Pham, C. G., Bubici, C., Zazzeroni, F., Knabb, J. R., Papa, S., Kuntzen, C., Franzoso, G.
(2007). Upregulation of Twist-1 by NF-{kappa}B Blocks Cytotoxicity Induced by Chemotherapeutic Drugs. Mol. Cell. Biol.
27: 3920-3935
[Abstract]
[Full Text]
-
Ouellet, S., Vigneault, F., Lessard, M., Leclerc, S., Drouin, R., Guerin, S. L.
(2006). Transcriptional regulation of the cyclin-dependent kinase inhibitor 1A (p21) gene by NFI in proliferating human cells. Nucleic Acids Res
34: 6472-6487
[Abstract]
[Full Text]
-
Rothschild, G., Zhao, X., Iavarone, A., Lasorella, A.
(2006). E Proteins and Id2 Converge on p57Kip2 To Regulate Cell Cycle in Neural Cells.. Mol. Cell. Biol.
26: 4351-4361
[Abstract]
[Full Text]
-
Guenou, H., Kaabeche, K., Mee, S. L., Marie, P. J.
(2005). A role for fibroblast growth factor receptor-2 in the altered osteoblast phenotype induced by Twist haploinsufficiency in the Saethre-Chotzen syndrome. Hum Mol Genet
14: 1429-1439
[Abstract]
[Full Text]
-
Liu, Y., Encinas, M., Comella, J. X., Aldea, M., Gallego, C.
(2004). Basic Helix-Loop-Helix Proteins Bind to TrkB and p21Cip1 Promoters Linking Differentiation and Cell Cycle Arrest in Neuroblastoma Cells. Mol. Cell. Biol.
24: 2662-2672
[Abstract]
[Full Text]
-
Kim, W., Kook, S., Kim, D. J., Teodorof, C., Song, W. K.
(2004). The 31-kDa Caspase-generated Cleavage Product of p130cas Functions as a Transcriptional Repressor of E2A in Apoptotic Cells. J. Biol. Chem.
279: 8333-8342
[Abstract]
[Full Text]
-
Funato, N., Ohyama, K., Kuroda, T., Nakamura, M.
(2003). Basic Helix-Loop-Helix Transcription Factor Epicardin/Capsulin/Pod-1 Suppresses Differentiation by Negative Regulation of Transcription. J. Biol. Chem.
278: 7486-7493
[Abstract]
[Full Text]
-
Wang, A., Gu, J., Judson-Kremer, K., Powell, K.L., Mistry, H., Simhambhatla, P., Aldaz, C. M., Gaddis, S., MacLeod, M. C.
(2003). Response of human mammary epithelial cells to DNA damage induced by BPDE: involvement of novel regulatory pathways. Carcinogenesis
24: 225-234
[Abstract]
[Full Text]
-
Mueller, K. L., Jacques, B. E., Kelley, M. W.
(2002). Fibroblast Growth Factor Signaling Regulates Pillar Cell Development in the Organ of Corti. J. Neurosci.
22: 9368-9377
[Abstract]
[Full Text]